Published in J Clin Endocrinol Metab on June 01, 2003
Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A (2003) 2.23
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev (2011) 1.21
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res (2005) 1.21
Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat (2008) 1.07
Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol (2007) 0.94
Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol Cancer Res (2010) 0.92
Putative role of prostaglandin receptor in intracerebral hemorrhage. Front Neurol (2012) 0.90
The role of n-3 polyunsaturated fatty acids in the prevention and treatment of breast cancer. Nutrients (2014) 0.89
Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod (2008) 0.87
Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience (2007) 0.86
Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells. J Biol Chem (2009) 0.86
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids (2007) 0.85
Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. Am J Pathol (2005) 0.85
Growth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms. J Steroid Biochem Mol Biol (2010) 0.82
EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation. Biochim Biophys Acta (2009) 0.80
The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors. Mol Carcinog (2011) 0.80
HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. Breast Cancer Res (2013) 0.78
Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae). Phytochem Lett (2009) 0.77
Mechanical phenotype is important for stromal aromatase expression. Steroids (2011) 0.77
Regulation of adipose oestrogen output by mechanical stress. Nat Commun (2013) 0.76
Abnormal Expression of Prostaglandins E2 and F2α Receptors and Transporters in Patients with Endometriosis. Biomed Res Int (2015) 0.75
Central administration of indomethacin mitigates the injury-induced upregulation of aromatase expression and estradiol content in the zebra finch brain. Endocrinology (2017) 0.75
Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab (2005) 1.56
Reconsidering the length of program accreditation. Am J Pharm Educ (2011) 1.44
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem (2006) 1.19
Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis (2003) 1.16
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther (2008) 1.15
Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol (2005) 1.13
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol (2006) 1.12
The final catalytic step of cytochrome p450 aromatase: a density functional theory study. J Am Chem Soc (2005) 1.08
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol (2002) 1.05
Are we producing innovators and leaders or change resisters and followers? Am J Pharm Educ (2012) 1.00
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist (2008) 0.99
Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem (2006) 0.99
Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int J Pharm (2010) 0.97
Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer. J Comb Chem (2008) 0.93
Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer. Cancer Res (2011) 0.92
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem (2007) 0.90
SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol Pharm (2011) 0.88
Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines. J Cell Biochem (2003) 0.88
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J Nat Prod (2006) 0.88
Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod (2008) 0.87
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids (2007) 0.85
Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification. J Med Chem (2008) 0.84
Increasing the DNA damage threshold in breast cancer cells. Toxicol Appl Pharmacol (2002) 0.84
Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine (2012) 0.83
Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain. Bioorg Med Chem Lett (2003) 0.83
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer (2011) 0.82
Natural products as aromatase inhibitors. Anticancer Agents Med Chem (2008) 0.82
Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg Med Chem (2005) 0.82
Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro. Int J Pharm (2012) 0.81
Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorg Med Chem (2005) 0.81
Influence of novel KGFR tyrosine kinase inhibitors on KGF-mediated proliferation of breast cancer. Anticancer Res (2010) 0.81
Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J Med Chem (2004) 0.80
Role of the azinomycin naphthoate and central amide in sequence-dependent DNA alkylation and cytotoxicity of epoxide-bearing substructures. Org Lett (2002) 0.80
Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. J Steroid Biochem Mol Biol (2007) 0.79
Maintaining pharmacy education's research focus as the academy expands. Am J Pharm Educ (2012) 0.78
Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae). Phytochem Lett (2009) 0.77
Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Res (2008) 0.76
Rapamycin-loaded immunoliposomes functionalized with trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells. Anticancer Agents Med Chem (2016) 0.75
Highly efficient cationic ethylphosphatidylcholine siRNA carrier for GFP suppression in modified breast cancer cells. Anticancer Res (2012) 0.75
4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells. J Steroid Biochem Mol Biol (2007) 0.75